Eligibility for faricimab in a real-world neovascular age-related macular degeneration population: a cross-sectional study

OBJECTIVES: To investigate the eligibility of a real-world neovascular age-related macular degeneration (nAMD) population for the TENAYA and LUCERNE trials (testing faricimab), and to compare the eligible real-world patients to trial participants. DESIGN, SETTINGS AND PARTICIPANTS: In this retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Jern, Iréne, Forsell, Sara, Norberg, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Ophthalmology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472139/
https://www.ncbi.nlm.nih.gov/pubmed/36096541
http://dx.doi.org/10.1136/bmjopen-2022-065001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472139/
https://www.ncbi.nlm.nih.gov/pubmed/36096541
http://dx.doi.org/10.1136/bmjopen-2022-065001

Ejemplares similares